The interventional cardiology market includes, but is not limited to, drug-eluting stents, bare-metal stents ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
January 31, 2013 — Biosensors International has announced CE mark approval for its polymer-free drug-coated stent (DCS) ...
January 16, 2013 — Just weeks after the Food and Drug Administration (FDA) approved Cook Medical’s Zilver PTX drug ...
January 8, 2013 — Abbott announced the initiation of the ABSORB III clinical trial in patients in the United States. The ...
January 7, 2013 — Biosensors International has announced enrollment of the first patient in LEADERS FREE, a clinical ...
January 3, 2013 — Abbott announced that the Xience Xpedition everolimus-eluting coronary stent system received U.S. Food ...
December 28, 2012 — Resuscitation, cell regeneration, a new high blood pressure treatment and developments in devices ...
December 20, 2012 — The first patient has been enrolled in the Boston Scientific EVOLVE II clinical trial, which is ...
November 15, 2012 — The U.S. Food and Drug Administration (FDA) granted market clearance for Cook Medical’s Zilver PTX ...
November 9, 2012 — Boston Scientific Corp. has received approval to update the directions for use (DFU) labeling for ...
October 31, 2012 — Boston Scientific Corp. received CE mark approval for the Synergy everolimus-eluting platinum ...
September 17, 2012 — The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report ...
August 20, 2012 — Abbott today announced that the Xience Xpedition everolimus-eluting coronary stent system received CE ...
Â
As the average age of the U.S. population and the number of patients at high risk for cardiovascular disease ...
June 21, 2012 — Plans for a new study involving BioFreedom, the polymer-free drug-coated stent (DCS) from Biosensors ...